Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GALR1 | P47211 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30107993 | 0.84 | CDK8 (0.54) | NPC1RAB9A | |
| SCHEMBL29617015 | 0.82 | TP53 (0.62) | TP53POLBHPGDNPC1RAB9A | |
| SCHEMBL4900084 | 0.82 | NPC1 (0.48) | TP53POLBHPGDNPC1RAB9A | |
| SCHEMBL1279251 | 0.82 | TP53 (0.46) | TP53POLBHPGDNPC1RAB9A | |
| SCHEMBL14759026 | 0.81 | CYP1A2 (0.53) | NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4193217 | 0.80 | TP53 (0.61) | TP53POLBHPGDGALR1 | |
| SCHEMBL2388712 | 0.80 | NPC1 (0.58) | TP53POLBHPGDNPC1RAB9A | |
| SCHEMBL29978844 | 0.80 | NPC1 (0.58) | TP53POLBHPGDNPC1RAB9A | |
| SCHEMBL6225292 | 0.80 | KDM4E (0.57) | TP53POLBHPGDKDM4EGALR1 | |
| SCHEMBL1513281 | 0.79 | CDK8 (0.50) | TP53POLBHPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-9315467-B2 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| EP-1799212-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044505-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | TP53 682/4885POLB 184/4885HPGD 3698/4885 |
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | TP53 682/4885POLB 184/4885HPGD 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.